These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35843487)

  • 21. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
    Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
    Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
    Terasaki H; Shiraki K; Ohji M; Metzig C; Schmelter T; Zeitz O; Sowade O; Kobayashi M; Vitti R; Berliner A; Shiraga F
    Retina; 2019 May; 39(5):938-947. PubMed ID: 29470308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
    Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
    Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
    Talcott KE; Valentim CCS; Hill L; Stoilov I; Singh RP
    Ophthalmol Retina; 2023 Jul; 7(7):605-611. PubMed ID: 36774994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
    Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
    Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies.
    Pieramici D; Singh RP; Gibson A; Saroj N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Soo Y; Zhu X; Boyer DS
    Ophthalmol Retina; 2018 Jun; 2(6):558-566. PubMed ID: 31047609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis.
    Ciulla TA; Kapik B; Grewal DS; Ip MS
    Ophthalmol Retina; 2021 Jul; 5(7):633-647. PubMed ID: 33130256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.
    Xie X; Lian C; Zhang Z; Feng M; Wang W; Yuan X; Shi Y; Liu T
    Front Endocrinol (Lausanne); 2023; 14():1144422. PubMed ID: 37260449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
    Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema.
    Hirano T; Toriyama Y; Takamura Y; Sugimoto M; Nagaoka T; Sugiura Y; Okamoto F; Saito M; Noda K; Yoshida S; Ishibazawa A; Sawada O; Murata T
    Sci Rep; 2021 Feb; 11(1):4488. PubMed ID: 33627712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.
    ; Scott IU; Edwards AR; Beck RW; Bressler NM; Chan CK; Elman MJ; Friedman SM; Greven CM; Maturi RK; Pieramici DJ; Shami M; Singerman LJ; Stockdale CR
    Ophthalmology; 2007 Oct; 114(10):1860-7. PubMed ID: 17698196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
    Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M
    Health Technol Assess; 2022 Dec; 26(50):1-86. PubMed ID: 36541393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema.
    Lai FHP; Chan RPS; Lai ACH; Tsang S; Woo TTY; Lam RF; Yuen CYF
    Jpn J Ophthalmol; 2021 Sep; 65(5):680-688. PubMed ID: 34125326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.